@article{ATM28054,
author = {Venugopal B. Bhattad and Sathvika Gaddam and Margaret A. Lassiter and Pooja S. Jagadish and Devarshi Ardeshna and Brandon Cave and Rami N. Khouzam},
title = {Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events},
journal = {Annals of Translational Medicine},
volume = {7},
number = {17},
year = {2019},
keywords = {},
abstract = {Cangrelor is a relatively new antiplatelet drug that has been approved for use as an adjunct therapy to percutaneous coronary intervention (PCI) to decrease peri-procedural myocardial infarction (MI), coronary revascularization, and stent thrombosis. Cangrelor is an adenosine triphosphate analogue with a pharmacokinetic mechanism based on a reversible, dose-dependent inhibition adenosine diphosphate (ADP)-induced platelet aggregation. This drug has lately been in the spotlight as a possible bridge therapy for anti-platelet medication prior to cardiac and non-cardiac surgeries. Platelet function is usually restored within sixty minutes of cessation of therapy, thereby decreasing the risk of bleeding while providing adequate pre-procedural coverage to reduce ischemic events. This manuscript reviews the literature on cangrelor and summarizes its role as a peri-procedural bridge.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/28054}
}